-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, BeOne's SEQUOIA Trial Shows BRUKINSA Plus Venetoclax Yields Deep, Durable Responses Across CLL Risk Groups Including del(17p) And TP53

Benzinga·06/02/2025 08:45:13
Listen to the news
  • BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational status
  • At 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data